Project: A novel targeted antibody treatment against BK virus-induced kidney graft rejection
| Acronym | BKVab (Reference Number: 113381) |
| Duration | 01/10/2019 - 03/10/2022 |
| Project Topic | This consortium aims to develop a therapeutic monoclonal antibody (mAb) as novel treatment to prevent BKV induced nephropathy and graft loss in kidney transplant recipients (KTRs). This project will deliver the therapeutic antibody with an associated efficacy and safety data package. The data package will be used to negotiate a license deal with a pharmaceutical company. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Memo Therapeutics AG | Coordinator | Switzerland |
| 2 | OcellO B.V. | Partner | Netherlands |
| 3 | Laboratory of Pharmacology and Toxicology (LPT) GmbH & Co. KG | Partner | Germany |